TAM
GERM

Tucker Asset Management’s Amplify Treatments, Testing and Advancements ETF GERM Stock Holding History

Tucker Asset Management’s Portfolio GERM Stock Details GERM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-231
Closed -$4.21K – 1711
2024
Q2 		$4.21K Hold
231
– – ﹤0.01% 1120
2024
Q1 		$4.25K Hold
231
– – ﹤0.01% 1134
2023
Q4 		$4.52K Hold
231
– – ﹤0.01% 933
2023
Q3 		$4.13K Hold
231
– – ﹤0.01% 872
2023
Q2 		$4.76K Hold
231
– – ﹤0.01% 699
2023
Q1 		$4.72K Hold
231
– – ﹤0.01% 721
2022
Q4 		$5.14K Hold
231
– – ﹤0.01% 436
2022
Q3 		$5.22K Buy
+231
New +$5.62K ﹤0.01% 422

Other funds holding GERM

IA
IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

Tucker Asset Management's GERM Position: Q3 2024 in Review

Tucker Asset Management sold out of Amplify Treatments, Testing and Advancements ETF (GERM) in Q3 2024, closing a stake of 231 shares — an estimated $4.21K sold.

Tucker Asset Management first reported a position in GERM in Q3 2022 and held it in 8 quarters. The position peaked at $5.22K in Q3 2022. 1 fund tracked by Wall St. Rank holds GERM as of Q3 2024.

  • Tucker Asset Management reported no remaining Amplify Treatments, Testing and Advancements ETF position as of Q3 2024 after selling out during the quarter.
  • Tucker Asset Management sold 231 Amplify Treatments, Testing and Advancements ETF shares in Q3 2024, an estimated $4.21K.
  • Tucker Asset Management first reported a position in Amplify Treatments, Testing and Advancements ETF in Q3 2022 and held it in 8 quarters.
  • Tucker Asset Management's Amplify Treatments, Testing and Advancements ETF position peaked at $5.22K in Q3 2022.
  • 1 fund tracked by Wall St. Rank held Amplify Treatments, Testing and Advancements ETF as of Q3 2024.

Based on Tucker Asset Management's 13F filing for Q3 2024, filed 3 Feb 2025.